Page 5 - Raquel Cona News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer

- Median Overall Survival for GPS Combination was 18.4 Months Compared to 13.8 months in a Checkpoint Inhibitor Single Agent Study in a Similar Patient Population Treated with Checkpoint Inhibitor. | November 10, 2022

United statesAngelos stergiouMichaela fawcettBruno bastosAllison sossRaquel conaHerbert wertheim college of medicineCompany wilmsGenfleet therapeutics shanghai incMerck co incStrategic communicationsLife sciences group incMerck sharp dohmeMiami cancer instituteMemorial sloan kettering cancer centerGlobenewswire inc

NEXGEL to Participate in Upcoming Investor Conferences in October 2022

NEXGEL to Participate in Upcoming Investor Conferences in October 2022
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesLos angelesValter pintoAdam levyDawson jamesRaquel conaStrategic communicationsHotel at los angelesWyndham grand hotel at jupiterNexgel incDawson james securitiesAnnual small cap growth conferenceJames securitiesWyndham grand hotelLuxe sunset boulevard hotel

NEXGEL to Present at the H C Wainwright 24th Annual Global Investment Conference from September 12-14, 2022

07.09.2022 - LANGHORNE, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced that .

New yorkUnited statesValter pintoAdam levyRaquel conaStrategic communicationsLotte new york palace hotelNexgel incAnnual global investment conferenceAnnual global investment

NEXGEL to Report its Second Quarter 2022 Financial and Operating Results on August 10th

04.08.2022 - Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel .

Valter pintoRaquel conaStrategic communications

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination is 53.9 percent compared to 37.2 percent in a checkpoint inhibitor. | May 26, 2022

United statesAngelos stergiouMichaela fawcettJeffreys weberAllison sossRaquel conaLangone healthCompany wilmsGenfleet therapeutics shanghai incMerck co incStrategic communicationsLife sciences group incYork universityMelanoma research program centerPerlmutter cancer centerMemorial sloan kettering cancer center